Contributing Member of the Healthcare Councils
Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.
GLG News by this Author
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
May 16, 2008
Anti-inflammatory Drugs Do Not Improve Cognitive Function in Older Adults | pharmalive.com
More contradictory data. But without a clear case, it does not make sense to prescribe NSAIDS to patients with AD.
-
May 8, 2008
Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus | www.pipelinereview.com
The problem with lupus studies lies in study design. While true for all trials, this is specially true for lupus since the disease is not "uniform". Patients have so many different varieties of lupus that the inclusion/exclusion criteria can make or break a study before it starts.
-
T cell reconstitution after transplant
May 1, 2008
Cytheris Announces New Phase I Study of Interleukin-7 As Immunotherapy In Treatment of Bone Marrow or Peripheral Blood Stem Cell Transplant Patients | www.pipelinereview.com
IL-7 is important for B and T cell development. But both cells require multiple cytokines, in the correct chronological order and appropriate amounts, for optimum results.
-
April 24, 2008
MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13 | www.pipelinereview.com
This is a better target than IL-5. But some of the issues are the same.
-
Stem cells for Mulitple Sclerosis
April 24, 2008
Pluristem's PLX Cells Show a Statistically Significant Advantage in a Pre-Clinical Study in the Multiple Sclerosis Model | www.pipelinereview.com
The battle between hype and hope continues.
-
April 24, 2008
Lexicon's Drug Candidate for Rheumatoid Arthritis, LX2931, Shows Positive Results in Phase 1 Clinical Trial | www.pipelinereview.com
To call these result positive is to be very optimistic.
-
April 24, 2008
CimziaA(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease | www.pipelinereview.com
Another anti-TNF for Crohns Disease. How will it stack up against the competition?
-
April 15, 2008
Where The Jobs Aren’t: Research & Development | www.pharmalot.com
To paraphrase, rumors of big pharma's demise are vastly exaggerated.
-
April 15, 2008
Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market | www.pipelinereview.com
This will provide a strong challenge to US and EU companies planning biosimilars
-
April 8, 2008
Amgen Drug Helps Bones | online.wsj.com
Osteoporosis treatment is becoming highly competitive. So how competitive is Denosumab's profile?
-
April 4, 2008
Big Pharma rushing for foothold in emerging markets despite challenges | www.pipelinereview.com
There are barriers to pharma companies in emerging markets, but if the companies want to make a few bucks, they do not have a choice.
-
April 4, 2008
Enbrel, Perception and Remicade Fostering a New Class of Drugs | www.pharmalive.com
This rather poorly written summary hides the potentials and pitfalls of biologics.
-
A red herring or a decoy? AVONTEC in asthma
March 24, 2008
AVONTEC announce results of a multiple dose clinical proof of concept study with its drug candidate AVT-01 decoy ODN in asthmatic patients | www.pipelinereview.com
AVONTECs AVT-01 (STAT 1) decoy did not work in the phase II study. Why?
-
Will Crohn's management follow RA?
March 17, 2008
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial | www.thelancet.com
As in RA, it seems that early aggressive therapy is better than conventional therapy.
-
March 17, 2008
Hematologic Malignant Neoplasms After Drug Exposure in Rheumatoid Arthritis | archinte.ama-assn.org
Nothing earth shattering in this analysis but it does give the practitioner a way to measure risk.
-
March 17, 2008
Glenmark’s molecule for Rheumatoid Arthritis - GRC 4039 | www.pipelinereview.com
PDE4 antagonists in RA could be interesting.
-
March 17, 2008
Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology | www.pipelinereview.com
I'd wait for the phase II results before getting too exicited about this.
-
February 4, 2008
New lease on life? The ethics of offshoring clinical trials | www.ft.com
This is a well balanced article, with clearly identified pros and cons
-
February 4, 2008
New Study Reports Enbrel (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents | www.wyeth.com
Expansion of label - good for Enbrel.
-
February 4, 2008
Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R)) | www.pipelinereview.com
What was missing in the article is as important as what was published.
- Subscribe to Updates
-
This author consults with leading institutions through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.